Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.60 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | TDP2 | O95551 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | CASP9 | P55211 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771998 | 0.89 | CDC25B (0.57) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4763653 | 0.86 | KDM4E (0.63) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4774175 | 0.85 | THRB (0.52) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4769021 | 0.80 | TNKS (0.64) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4773592 | 0.78 | THRB (0.52) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4766308 | 0.78 | GUSB (0.60) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4771349 | 0.77 | TNKS (0.54) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL4768926 | 0.75 | KDM4E (0.63) | CDC25BAPAF1TDP2CASP3CASP7 | |
| SCHEMBL1536353 | 0.73 | KDM4E (0.64) | CASP3SENP8SENP7GUSBTNKS | |
| SCHEMBL1536409 | 0.73 | CDC25B (0.43) | CDC25BAPAF1TDP2CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CDC25B 258/4885APAF1 3367/4885TDP2 1379/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | CDC25B 1388/4885APAF1 3549/4885TDP2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.